The FACS analysis conducted on nine different cell types, including cancer and primary cells, treated with Fib(GFP) and Par(GFP) showed that only approximately 1–7% of the cells that had been treated with Par(GFP) generated fluorescence, while the Fib(GFP)-treated cells showed much higher uptake rates. This evidence concerns the gene FBL and cancer.